Home > Rheumatology > EULAR 2020 > Psoriatic Arthritis > Adalimumab added to methotrexate yields better results in PsA than methotrexate escalation

Adalimumab added to methotrexate yields better results in PsA than methotrexate escalation

Results from the ongoing phase 4 CONTROL trial shows that adding adalimumab to the treatment regimen of methotrexate results in better outcomes than methotrexate dose escalation in patients with psoriatic arthritis (PsA) who did not respond sufficiently to initial methotrexate therapy [1].

The study, presented by Dr Laura Coates (Oxford University, United Kingdom), enrolled 245 biologic-naïve patients with active psoriatic arthritis despite treatment with methotrexate for at least 4 weeks. Patients were randomised to add-on adalimumab 40 mg every 2 weeks (n=123) or methotrexate dose escalation to a maximum of 20-25 mg/week (n=122; the average dose of methotrexate was 21.8 mg/week).

At week 16, the results showed that 41.5% of patients who were treated with adalimumab achieved minimal disease activity (MDA) compared with 13.1% MDA of patients who received methotrexate escalation treatment. The significantly higher rates of MDA in the adalimumab group...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on